Valuation: AbbVie Inc.

Market Cap 450B 394B 363B 336B 638B 42,701B 649B 4,351B 1,692B 21,074B 1,689B 1,653B 72,840B P/E 2026 *
31.1x
P/E 2027 * 23.9x
Enterprise Value 506B 443B 408B 378B 718B 47,997B 729B 4,891B 1,902B 23,688B 1,899B 1,858B 81,875B EV / Sales 2026 *
7.52x
EV / Sales 2027 * 6.82x
Free-Float
95.71%
Yield 2026 *
2.69%
Yield 2027 * 2.84%
1 day-0.04%
1 week+1.20%
Current month+1.20%
1 month+12.07%
3 months+23.39%
6 months+9.10%
Current year+11.45%
1 week 250.51
Extreme 250.51
261.64
1 month 215.37
Extreme 215.37
261.64
Current year 190.75
Extreme 190.75
261.64
1 year 184.63
Extreme 184.63
261.64
3 years 132.7
Extreme 132.7
261.64
5 years 105.56
Extreme 105.56
261.64
10 years 55.06
Extreme 55.0623
261.64
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 68 2012-12-31
Date Insider Type Main position Quantity % Market Cap.
06-29Free

Director

62 0.0000%
06-29Free

Director

134 0.0000%
05-07Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%+1.20%+35.72%+87.93% 450B
+2.96%+3.01%+59.87%+173.31% 1,070B
+3.05%+5.23%+72.11%+67.81% 624B
-2.58%-2.07%+27.62%+22.57% 328B
+1.36%+0.17%+29.90%+49.33% 284B
+1.98%+4.08%-25.78%-39.02% 217B
+0.45%+1.65%+25.65%+68.35% 198B
+5.21%+7.93%+21.99%+83.23% 161B
+1.48%-0.04%-4.64%-32.25% 135B
-1.39%+5.14%+13.68%+54.43% 134B
Average +0.63%+2.00%+25.61%+53.57% 360.19B
Weighted average by Cap. +1.39%+1.76%+40.79%+86.12%

Financials

2026 *2027 *
Net sales 67.24B 58.84B 54.23B 50.26B 95.41B 6,381B 96.95B 650B 253B 3,149B 252B 247B 10,886B 72.73B 63.65B 58.66B 54.37B 103B 6,903B 105B 703B 274B 3,407B 273B 267B 11,776B
Net income 14.56B 12.74B 11.74B 10.88B 20.66B 1,382B 21B 141B 54.76B 682B 54.67B 53.48B 2,357B 19.02B 16.65B 15.34B 14.22B 26.99B 1,805B 27.43B 184B 71.54B 891B 71.42B 69.87B 3,080B
Net Debt 55.81B 48.84B 45.01B 41.72B 79.2B 5,297B 80.47B 540B 210B 2,614B 210B 205B 9,035B 46.34B 40.55B 37.37B 34.64B 65.75B 4,398B 66.81B 448B 174B 2,170B 174B 170B 7,502B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-07-07 US$254.65 -0.04% 8,238,085
26-07-06 US$254.76 -2.42% 8,580,220
26-07-02 US$261.07 +3.99% 7,114,422
26-07-01 US$251.06 -0.23% 6,987,982
26-06-30 US$251.64 -1.05% 6,999,707
Trader
Investor
Global
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
254.65USD
Average target price
258.32USD
Spread / Average Target
+1.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock